TianyinPharmaceutical, Co., Inc., (OTC Bulletin Board: TYNP - News), a manufacturerand supplier of modernized traditional Chinese medicine ("TCM") based inChengdu, China, today announced that its common stock will begin trading onthe American Stock Exchange (the "AMEX") under the ticker "TPI" at market openon Wednesday, October 1, 2008. "Moving to the AMEX is a landmark for our Company. We expect that tradingon the AMEX will elevate our Company's standing within the internationalbusiness community, as well as our visibility among the investment community,"Dr. Jiang, Chairman and CEO of Tianyin commented. "I would like to thank bothTripoint Capital Advisors, the financial advisor for Tianyin Pharmaceuticals,and CMARK Capital, Tripoint's partner in China, for being instrumental withthe transition and activities since our Company became public." The AMEX Panel's approval is contingent upon the Company being in directcompliance with the Alternative Listing Standards at the time the Company'scommon shares begin trading on the AMEX, and may be rescinded if the Companyis not in compliance with such standards. Once Tianyin's common sharescommence trading on the AMEX, the Company will enjoy all of the sameprivileges and be subject to all of the same regulations as any other companywhose shares are listed on the AMEX, regardless of the Listing Standard usedto determine the Company's eligibility. Profile: Opening the gateway to China...   more

All the drugs in the Essential Drug List will be included in China\'s basic health insurance catalog with a higher reimbursement percentage....   more

Tianyin Pharmaceutical announced it received GMP certification for its new solid dosage manufacturing facility from the SFDA. The company said the new facility will triple its solid dose capacity. Tianyin, which has historically concentrated in TCM, has been branching out into generic versions of western drugs....   more

Tianyin Pharmaceutical Co., a developer, manufacturer and supplier of modernized traditional Chinese medicine (TCM) and generic pharmaceuticals in China, reported that for the fiscal year ended June 30, 2009, its revenues have increased 28.2% to $42.9 million from $33.5 million reported for the prior year period....   more